Please login to the form below

Not currently logged in
Email:
Password:

EMA reviews Multaq's CVD risk

The European Medicines Agency is to review the cardiovascular risk of Sanofi's anti-arrhythmic medicine Multaq following serious adverse events in the company's discontinued PALLAS study

The European Medicines Agency (EMA) is to review the cardiovascular risk of Sanofi's anti-arrhythmic medicine Multaq (dronedarone) following serious adverse events in the company's discontinued PALLAS study.

Results from the study, which investigated the effects of Multaq in more than 3,149 patients over 65 years of age with permanent atrial fibrillation, found a higher rate of events and hospitalisations with Multaq when compared with placebo.

The EMA pointed out that the patient population involved in the PALLAS study is different from the population for which Multaq is currently approved.

A review by the Agency's Committee for Medicinal Products for Human Use (CHMP) concerning the benefit-risk balance of Multaq following reports of severe liver injury commenced in January, with the scope of this review now extended to also assess new information from the PALLAS study.

The CHMP will determine the need for any further action at its next meeting on July 18-21, 2011.

12th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics